Free tool
Rare disease stocks
We cover 43 companies grouped under the Rare disease theme. The median market value in the group is $23.74M. Across the group, the median move over the past trading day is +1.27%. 26% of the 42 with a 200-day average trade above it. Price change over the past year runs from −93.3% to +132.4% across the middle 80 percent of the group, with a median of −48.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
43 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | $0.20 | +2.76% | −92.90% | −91.33% |
| FBIO | Fortress Biotech, Inc. | $2.83 | −13.46% | −29.78% | +23.58% |
| PLYX | Polaryx Therapeutics, Inc. | $1.87 | −4.59% | −94.66% | −94.66% |
| RLYB | Rallybio Corporation | $16.89 | +3.53% | +198.53% | +262.65% |
| TENX | Tenax Therapeutics, Inc. | $2.32 | −85.67% | −79.00% | −60.81% |
| TELO | Telomir Pharmaceuticals, Inc. | $1.18 | −4.07% | −11.94% | −19.18% |
| FBIOP | Fortress Biotech, Inc. | $18.30 | −2.66% | +80.12% | +141.55% |
| SPRO | Spero Therapeutics, Inc. | $1.23 | +4.24% | −47.66% | −33.51% |
| RNTX | Rein Therapeutics Inc. | $0.80 | +2.30% | −36.00% | −32.20% |
| IMA | ImageneBio, Inc. | $5.55 | −0.89% | −17.90% | −60.78% |
| ATYR | aTyr Pharma, Inc. | $0.57 | +16.33% | −24.90% | −88.95% |
| SCYX | SCYNEXIS, Inc. | $5.19 | +45.38% | +712.21% | +514.20% |
| NSRX | Nasus Pharma Ltd. | $4.10 | +32.69% | −45.70% | −48.69% |
| MCRB | Seres Therapeutics, Inc. | $5.00 | +3.09% | −67.00% | −74.00% |
| GRCE | Grace Therapeutics, Inc. | $2.20 | −4.35% | −39.89% | −32.31% |
| MREO | Mereo BioPharma Group plc | $0.28 | −6.75% | −44.78% | −83.82% |
| EDSA | Edesa Biotech, Inc. | $4.45 | −16.82% | +196.67% | +83.88% |
| QNCX | Quince Therapeutics, Inc. | $30.93 | +73.28% | +3.10% | +95.76% |
| NNVC | NanoViricides, Inc. | $1.29 | −16.23% | +6.61% | −12.84% |
| BRNS | Barinthus Biotherapeutics plc | $0.66 | +9.82% | −10.20% | −44.77% |
| JSPR | Jasper Therapeutics, Inc. | $0.72 | +3.78% | −60.86% | −75.67% |
| TVRD | Tvardi Therapeutics, Inc. | $1.82 | −28.35% | −55.39% | −93.77% |
| COCP | Cocrystal Pharma, Inc. | $1.13 | +22.83% | +14.14% | −26.62% |
| VYNE | VYNE Therapeutics Inc | $28.56 | +3080.40% | +4824.14% | +8687.69% |
| KTTA | Pasithea Therapeutics Corp. | $0.56 | +24.44% | −52.94% | −21.90% |
| CALC | CalciMedica, Inc. | $0.59 | −16.36% | −91.28% | −78.92% |
| CMMB | Chemomab Therapeutics Ltd. | $2.30 | +61.97% | +28.49% | −33.91% |
| HIND | Vyome Holdings, Inc. | $2.23 | +11.50% | −37.18% | −80.23% |
| QNRX | Quoin Pharmaceuticals, Ltd. | $5.07 | +18.18% | −63.99% | −31.02% |
| AZTR | Azitra, Inc. | $0.16 | +23.05% | −43.55% | −78.97% |
| IMRN | Immuron Limited | $1.14 | +7.55% | +43.40% | −36.84% |
| SNGX | Soligenix, Inc. | $0.41 | +12.53% | −71.47% | −87.06% |
| XCUR | Exicure, Inc. | $1.19 | −32.00% | −78.67% | −79.90% |
| INM | InMed Pharmaceuticals Inc. | $1.44 | −12.20% | +28.57% | −35.43% |
| PULM | Pulmatrix, Inc. | $1.60 | −7.51% | −29.20% | −67.81% |
| JAGX | Jaguar Health, Inc. | $0.92 | −7.51% | −97.35% | −98.52% |
| CVKD | Cadrenal Therapeutics, Inc. | $1.53 | −25.73% | −79.13% | −87.58% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.31 | +716.94% | +423.12% | +205.34% |
| GRI | GRI Bio, Inc. | $1.96 | +40.00% | −75.00% | −95.14% |
| XRTX | XORTX Therapeutics Inc. | $2.26 | +11.88% | −20.70% | −44.74% |
| SXTP | 60 Degrees Pharmaceuticals, Inc. | $1.13 | −28.03% | −45.25% | −78.10% |
| MTNB | Matinas BioPharma Holdings, Inc. | $0.20 | −40.57% | −68.18% | −90.82% |
| VBIO | Valion Bio, Inc. | $0.16 | −43.82% | −88.80% | −95.00% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.